Author:
Colleoni Marco,Goldhirsch Aron
Reference9 articles.
1. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer;Kaufmann;Ann Surg Oncol,2012
2. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013;Goldhirsch;Ann Oncol,2013
3. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012
4. Pathological complete response and accelerated drug approval in early breast cancer;Prowell;N Engl J Med,2012
5. Neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel, with or without gemcitabine, for women with high-risk early breast cancer (Neo-tAnGo): an open-label, factorial, randomised phase 3 trial;Earl;Lancet Oncol,2013
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献